Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies

被引:111
作者
Sharma, SK
Ferreira, JL
Eblen, BS
Whiting, RC
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
D O I
10.1128/AEM.72.2.1231-1238.2006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
An amplified enzyme-linked immunosorbent assay (ELISA) for the detection of Clostridium botulinum complex neurotoxins was evaluated for its ability to detect these toxins in food. The assay was found to be suitable for detecting type A, B, E, and F botulinum neurotoxins in a variety of rood matrices representing liquids, solid, and semisolid food. Specific foods included broccoli, orange juice, bottled water, cola soft drinks, vanilla extract, oregano, potato salad, apple juice, meat products, and dairy foods. The detection sensitivity of the test for these botulinum complex serotypes was found to be 60 pg/ml (1.9 50% lethal dose [LD50]) for botulinum neurotoxin type A (BoNT/A), 176 pg/ml (1.58 LD50) for BoNT/B, 163 pg/ml for BoNT/E (4.5 LD50), and 117 pg/ml for BoNT/F (less than 1 LD50) in casein buffer. The test could also readily detect 2 ng/ml of neurotoxins type A, B, E, and F in a variety of food samples. For specificity studies., the assay was also used to test a large panel of type A C. botulinum, a smaller panel of proteolytic and nonproteolytic type B, E, and F neurotoxin-producing Clostridia, and nontoxigenic organisms using an overnight incubation of toxin production medium. The assay appears to be an effective tool for large-scale screening of the food supply in the event of a botulinum neurotoxin contamination event.
引用
收藏
页码:1231 / 1238
页数:8
相关论文
共 49 条
[1]  
ANDREADIS JD, 2003, FUTURE DIRECTIONS BI
[2]  
[Anonymous], 1989, BOTULINUM NEUROTOXIN, DOI DOI 10.1016/B978-0-12-644445-2.50021-0
[3]  
[Anonymous], 1988, IMMUNOCHEMISTRY PRAC
[4]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[5]  
BINZ T, 1990, J BIOL CHEM, V265, P9153
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   Electron density projection map of the botulinum neurotoxin 900-kilodalton complex by electron crystallography [J].
Burkard, F ;
Chen, F ;
Kuziemko, GM ;
Stevens, RC .
JOURNAL OF STRUCTURAL BIOLOGY, 1997, 120 (01) :78-84
[8]   Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species [J].
Chen, F ;
Kuziemko, GM ;
Stevens, RC .
INFECTION AND IMMUNITY, 1998, 66 (06) :2420-2425
[9]   Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms [J].
Chen, F ;
Kuziemko, GM ;
Amersdorfer, P ;
Wong, C ;
Marks, JD ;
Stevens, RC .
INFECTION AND IMMUNITY, 1997, 65 (05) :1626-1630
[10]   ENZYME-LINKED IMMUNOSORBENT-ASSAY FOR DETECTION OF CLOSTRIDIUM-BOTULINUM TYPE-A AND TYPE-B TOXINS IN STOOL SAMPLES OF INFANTS WITH BOTULISM [J].
DEZFULIAN, M ;
HATHEWAY, CL ;
YOLKEN, RH ;
BARTLETT, JG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1984, 20 (03) :379-383